Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antihypertensive Drugs: Potassium-Sparing Diuretics01:28

Antihypertensive Drugs: Potassium-Sparing Diuretics

2.7K
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
2.7K
Roles of Electrolytes: Sodium and Potassium01:24

Roles of Electrolytes: Sodium and Potassium

3.2K
Sodium plays a crucial role in maintaining fluid and electrolyte balance and overall bodily homeostasis. Sodium balance is primarily regulated by kidney function, which adjusts sodium elimination to match dietary intake and maintain proper electrolyte levels. Sodium is the most abundant cation in the extracellular fluid (ECF) and is found in salts such as sodium chloride (NaCl) and sodium bicarbonate (NaHCO3). Although cellular plasma membranes are relatively impermeable to sodium, its role in...
3.2K
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

4.4K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
4.4K
Ionic Bonds00:42

Ionic Bonds

136.6K
Overview
When atoms gain or lose electrons to achieve a more stable electron configuration they form ions. Ionic bonds are electrostatic attractions between ions with opposite charges. Ionic compounds are rigid and brittle when solid and may dissociate into their constituent ions in water. Covalent compounds, by contrast, remain intact unless a chemical reaction breaks them.
Opposing Charges Hold Ions Together in Ionic Compounds
Ionic bonds are reversible electrostatic interactions between ions...
136.6K
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

3.1K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
3.1K
Regulation of Sodium and Potassium01:26

Regulation of Sodium and Potassium

3.1K
The regulation of sodium and potassium ion concentrations in the human body is a complex process governed primarily by hormones such as aldosterone, antidiuretic hormone (ADH), and atrial natriuretic peptide (ANP).
Sodium Regulation
Sodium ions make up approximately 90% of extracellular cations, with a normal blood plasma concentration of 136–148 mEq/L. A decrease in blood volume and pressure triggers the release of renin from granular cells in the juxtaglomerular complex (JGC), primarily...
3.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Effectiveness of Ultrasound Biofeedback as a Muscle Retraining Tool Post Patellar Tendon Debridement Surgery: A Case Report.

Clinical case reports·2026
Same author

Beyond ST Elevation: Recognizing Wellens Syndrome and the de Winter Pattern as High-Risk LAD Ischemia.

Cardiology in review·2026
Same author

Polymeric mixed micellar nanogel enhances dermal delivery and therapeutic efficacy of tofacitinib citrate.

International journal of pharmaceutics·2026
Same author

Elobixibat Versus Prucalopride in Functional Constipation: A Prospective Comparative Effectiveness Study.

Alimentary pharmacology & therapeutics·2026
Same author

Bone Marrow Amyloidosis Without Detectable Plasma Cell Dyscrasia: A Diagnostic Pathologist's Challenge.

Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion·2026
Same author

Hypertension knowledge gaps: A patient-caregiver comparison from a tertiary care centre in Northern India.

Heart international·2026

Related Experiment Video

Updated: Apr 20, 2026

Voltage-Dependent Potassium Current Recording on H9c2 Cardiomyocytes via the Whole-Cell Patch-Clamp Technique
08:11

Voltage-Dependent Potassium Current Recording on H9c2 Cardiomyocytes via the Whole-Cell Patch-Clamp Technique

Published on: November 11, 2022

3.8K

Sodium zirconium cyclosilicate in hyperkalemia.

David K Packham1, Henrik S Rasmussen, Philip T Lavin

  • 1From the Melbourne Renal Research Group, the Department of Medicine, University of Melbourne, and the Department of Nephrology, Royal Melbourne Hospital, Melbourne, VIC (D.K.P.), and Renal Research, Gosford, NSW (S.D.R.) - both in Australia; ZS Pharma, Coppell (H.S.R., B.S.), and the University of Texas Health Science Center at San Antonio (W.Q.) and Renal Associates (P.P.), San Antonio - all in Texas; Boston Biostatistics Research Foundation, Framingham, MA (P.T.L.); Academic Medical Research Institute, Los Angeles (M.A.E.-S.), and Apex Research, Riverside (B.S.) - both in California; and Denver Nephrologists, Denver, (G.B.).

The New England Journal of Medicine
|November 22, 2014
PubMed
Summary

Sodium zirconium cyclosilicate (ZS-9) effectively lowers serum potassium in hyperkalemia patients. This novel treatment demonstrated significant potassium reduction and maintained normokalemia over 12 days, with similar adverse event rates to placebo.

More Related Videos

Contractions of Human-iPSC-derived Cardiomyocyte Syncytia Measured with a Ca-sensitive Fluorescent Dye in Temperature-controlled 384-well Plates
07:42

Contractions of Human-iPSC-derived Cardiomyocyte Syncytia Measured with a Ca-sensitive Fluorescent Dye in Temperature-controlled 384-well Plates

Published on: October 18, 2018

6.8K
Adsorption Device Based on a Langatate Crystal Microbalance for High Temperature High Pressure Gas Adsorption in Zeolite H-ZSM-5
09:46

Adsorption Device Based on a Langatate Crystal Microbalance for High Temperature High Pressure Gas Adsorption in Zeolite H-ZSM-5

Published on: August 25, 2016

12.4K

Related Experiment Videos

Last Updated: Apr 20, 2026

Voltage-Dependent Potassium Current Recording on H9c2 Cardiomyocytes via the Whole-Cell Patch-Clamp Technique
08:11

Voltage-Dependent Potassium Current Recording on H9c2 Cardiomyocytes via the Whole-Cell Patch-Clamp Technique

Published on: November 11, 2022

3.8K
Contractions of Human-iPSC-derived Cardiomyocyte Syncytia Measured with a Ca-sensitive Fluorescent Dye in Temperature-controlled 384-well Plates
07:42

Contractions of Human-iPSC-derived Cardiomyocyte Syncytia Measured with a Ca-sensitive Fluorescent Dye in Temperature-controlled 384-well Plates

Published on: October 18, 2018

6.8K
Adsorption Device Based on a Langatate Crystal Microbalance for High Temperature High Pressure Gas Adsorption in Zeolite H-ZSM-5
09:46

Adsorption Device Based on a Langatate Crystal Microbalance for High Temperature High Pressure Gas Adsorption in Zeolite H-ZSM-5

Published on: August 25, 2016

12.4K

Area of Science:

  • Nephrology
  • Cardiology
  • Endocrinology

Background:

  • Hyperkalemia is linked to increased mortality in patients with heart failure, chronic kidney disease, or diabetes.
  • Investigating novel treatments for hyperkalemia is crucial for improving patient outcomes.

Purpose of the Study:

  • To evaluate the efficacy of sodium zirconium cyclosilicate (ZS-9) in reducing serum potassium levels in patients with hyperkalemia.
  • To assess the safety and tolerability of ZS-9 during acute and maintenance phases of treatment.

Main Methods:

  • A multicenter, two-stage, double-blind, phase 3 trial involving 753 hyperkalemic patients.
  • Patients received varying doses of ZS-9 or placebo for 48 hours, followed by a maintenance phase.
  • Primary endpoint: exponential rate of change in mean serum potassium level at 48 hours.

Main Results:

  • ZS-9 significantly reduced serum potassium levels at 48 hours across multiple doses (2.5g, 5g, 10g) compared to placebo.
  • Normokalemia was maintained for 12 days in patients receiving 5g or 10g of ZS-9 during the maintenance phase.
  • Adverse event rates were comparable between ZS-9 and placebo groups, with diarrhea being the most common complication.

Conclusions:

  • Sodium zirconium cyclosilicate (ZS-9) is effective in lowering serum potassium levels in hyperkalemic patients.
  • ZS-9 provides sustained normokalemia during maintenance therapy.
  • The safety profile of ZS-9 is similar to placebo, suggesting a favorable risk-benefit ratio.